Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411098 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01411098 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 6 participants.
The verdict
NCT01411098, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of radiation therapy when given together with cisplatin and etoposide in treating patients with non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Drugs, such as cisplatin, may make tumor cells more sensitive to radiation therapy. Giving radiation therapy together with cisplatin and etoposide may kill more tumor cells.
Interventions
- DRUG cisplatin
- RADIATION intensity-modulated radiation therapy
- DRUG etoposide
- RADIATION 3-dimensional conformal radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01411098
The ClinicalTrials.gov registry entry for NCT01411098 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT01411098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01411098 about?
NCT01411098 is a clinical study titled "Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery". This phase I trial studies the side effects and best dose of radiation therapy when given together with cisplatin and etoposide in treating patients with non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemoth...
What is the current status of trial NCT01411098?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-10.
What interventions are being tested in trial NCT01411098?
The interventions under investigation include: cisplatin (DRUG), intensity-modulated radiation therapy (RADIATION), etoposide (DRUG), 3-dimensional conformal radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01411098?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.